International Journal of Colorectal Disease

, Volume 23, Issue 11, pp 1033–1039

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

  • C. I. Müller
  • K. Schulmann
  • A. Reinacher-Schick
  • N. Andre
  • D. Arnold
  • A. Tannapfel
  • H. Arkenau
  • S. A. Hahn
  • S. H.-J. Schmoll
  • R. Porschen
  • W. Schmiegel
  • U. Graeven
Original Article

DOI: 10.1007/s00384-008-0504-2

Cite this article as:
Müller, C.I., Schulmann, K., Reinacher-Schick, A. et al. Int J Colorectal Dis (2008) 23: 1033. doi:10.1007/s00384-008-0504-2

Abstract

Background and aims

Microsatellite instability (MSI) is a potential indicator of prognosis in patients with colorectal cancer (CRC). To date, there are a limited number of studies which investigated its role in advanced CRC. Our study investigated the value of high degree of MSI (MSI-H) in patients treated with 5-FU/oxaliplatin-based chemotherapy which has been done by only one further study recently.

Patients and methods

In this study, we investigated tumour tissues from 108 patients with metastatic CRC who were treated in a prospective, randomised trial comparing two oxaliplatin and 5-FU-based therapy regimens (FUFOX vs. CAPOX) involving a total of 474 patients. We determined the incidence and prognostic value of a high degree of microsatellite instability. The specimens were analysed by PCR corresponding to the National Institute of Health reference panel. In addition, immunostaining of the mismatch repair proteins MLH1, MSH2 and MSH6 was performed.

Results and findings

The incidence of MSI-H was 4%. MSI-H was correlated with a lower rate of disease control compared to non-MSI-H patients (p = 0.02). However, there was no correlation between MSI-H and progression-free survival or overall survival.

Interpretation and conclusion

MSI-H incidence in metastatic CRC was low. Our data suggest that MSI-H may be correlated with a poorer response to a 5-FU/oxaliplatin treatment. This finding needs confirmation in a larger cohort.

Keywords

Colorectal cancerMicrosatellite instabilityChemotherapyPrognosis

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • C. I. Müller
    • 1
  • K. Schulmann
    • 2
  • A. Reinacher-Schick
    • 2
  • N. Andre
    • 2
  • D. Arnold
    • 3
  • A. Tannapfel
    • 4
  • H. Arkenau
    • 5
  • S. A. Hahn
    • 6
  • S. H.-J. Schmoll
    • 3
  • R. Porschen
    • 7
  • W. Schmiegel
    • 2
    • 8
  • U. Graeven
    • 9
  1. 1.Institute of PhysiologyUniversity Hospital EssenEssenGermany
  2. 2.Medical DepartmentRuhr-University of BochumBochumGermany
  3. 3.Medical Department IV, University ClinicMartin Luther UniversityHalleGermany
  4. 4.Institute of Pathology, University Clinic BergmannsheilRuhr-University of BochumBochumGermany
  5. 5.Drug Development UnitRoyal Marsden Hospital and Institute of Cancer ResearchSuttonUK
  6. 6.Center for Clinical Research (ZKF, Molecular GI-Oncology (MGO))Ruhr-University of BochumBochumGermany
  7. 7.Medical Department Klinikum Bremen-OstBremenGermany
  8. 8.Division of Gastroenterology and Hepatology, University Hospital BergmannsheilRuhr-University of BochumBochumGermany
  9. 9.Kliniken Maria Hilf GmbH Klinik für Hämatologie, Onkologie, GastroenterologieMönchengladbachGermany